Reliable serum biomarkers are of immense need for diagnostic purposes of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)—a disabling and complex disease for which diagnosis is mainly based on clinical symptoms. The aim of this study was to evaluate a possible diagnostic potential of activin B by directly comparing 134 cases of ME/CFS with 54 healthy controls. Analyses of human activin B level in plasma samples were performed using a validated human activin B ELISA assay. The results of the study show that activin B levels did not differ statistically significantly between ME/CFS patients and healthy controls (p = 0.6511). No gender or age‐related differences in activin B levels were observed in the ME/CFS group and healthy controls. The level of activin B tended to decrease with increasing visual analogue scale score (r = −0.2004; p = 0.5085) nevertheless the results obtained so far does not support the clinical utility of activin B as a bi-omarker for ME/CFS.
|Number of pages||9|
|Publication status||Published - 11 Aug 2021|
- Human activin B
- Visual analogue scale
Field of Science*
- 3.1 Basic medicine
- 1.1. Scientific article indexed in Web of Science and/or Scopus database
FingerprintDive into the research topics of 'Potential of activin b as a clinical biomarker in myalgic encephalomyelitis/chronic fatigue syndrome (Me/cfs)'. Together they form a unique fingerprint.
Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome
Grāvelsiņa, S. (Creator), Vilmane, A. (Creator), Svirskis, Š. (Creator), Krūmiņa, A. (Creator) & Murovska, M. (Creator), Riga Stradins University, 18 Nov 2022
DOI: doi:10.48510/FK2/FLLDQX, https://dataverse.rsu.lv/dataset.xhtml?persistentId=doi:10.48510/FK2/FLLDQX